Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-9-13
|
pubmed:abstractText |
Blood pressure, proteinuria, and plasma fibronectin and plasminogen activator inhibitor-1 levels were measured in 120 apparently healthy normotensive primigravid women during the first, second, and third trimesters of pregnancy and 2 days post partum. Thirty-two women developed hypertension (diastolic blood pressure greater than or equal to 90 mm Hg) that in 17 women was associated with proteinuria (greater than 0.3 gm/day). Fibronectin levels were 83% +/- 22% of normal (mean +/- SD) during the first trimester and 75% +/- 20% at term in the healthy women but increased from 94% +/- 36% to 187% +/- 36% in the women who developed gestational hypertension (with or without proteinuria) (p less than 0.0001). Plasminogen activator inhibitor-1 levels increased from 26 +/- 19 ng/ml to 110 +/- 86 ng/ml in healthy women and from 32 +/- 35 ng/ml to 290 +/- 90 ng/ml in hypertensive women (p less than 0.001). Increased levels of fibronectin at 25 to 36 weeks of pregnancy (greater than or equal to mean + 2 SD of the healthy women, or greater than 140%) were found in 31 of the 32 women with gestational hypertension with or without proteinuria and in 5 of the 88 healthy women (sensitivity 96%, specificity 94%). Fibronectin levels increased 3.6 +/- 1.9 weeks earlier than the onset of hypertension and/or proteinuria. Increased levels of plasminogen activator inhibitor-1 at 25 to 32 weeks (greater than or equal to 280 ng/ml) were found in 16 of the 32 women who developed gestational hypertension with or without proteinuria and in 4 of the 88 healthy women (sensitivity 50%, specificity 95%). We conclude that increased fibronectin levels are the best predictor of gestational hypertension with or without proteinuria and that its level in plasma increases several weeks before the development of hypertension.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0002-9378
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
161
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
432-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2504045-Female,
pubmed-meshheading:2504045-Fibronectins,
pubmed-meshheading:2504045-Glycoproteins,
pubmed-meshheading:2504045-Humans,
pubmed-meshheading:2504045-Hypertension,
pubmed-meshheading:2504045-Plasminogen Activators,
pubmed-meshheading:2504045-Plasminogen Inactivators,
pubmed-meshheading:2504045-Postpartum Period,
pubmed-meshheading:2504045-Pre-Eclampsia,
pubmed-meshheading:2504045-Pregnancy,
pubmed-meshheading:2504045-Prognosis,
pubmed-meshheading:2504045-Prospective Studies,
pubmed-meshheading:2504045-Proteinuria
|
pubmed:year |
1989
|
pubmed:articleTitle |
Predictive value of increased plasma levels of fibronectin in gestational hypertension.
|
pubmed:affiliation |
Center for Thrombosis and Vascular Research, University of Leuven, Campus Gasthuisberg, Belgium.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|